**7. Treatment of peripheral neuropathy in ANCA-associated vasculitis**

The treatment is based on induction therapy and maintenance therapy. Unfortunately, there is not an universal protocol (dose or duration) for each form of therapy. Induction therapy is based in the combination of corticosteroids and cyclophosphamideor rituximab. Standard initial therapy consist of high-dose corticosteroids (prednisone 1 mg/kg/day) or IV methylprednisolone (1 g every day for three days and then once a week for three months) followed by a taper. Pulses of methylprednisolone are used in severe cases (i.e., mononeuritis multiplex and organ-threatening disease). Pulse IV cyclophosphamide (1 g/m2 per month for six months; or 15 mg/kg every two weeks for three doses and then every three weeks for three to six months) is simultaneously started with corticosteroids, especially in more severe cases. Cyclophosphamide is adjusted by age (>60 years) and to renal function and leukocyte counts. IV Rituximab at 375 mg/m2 per week for four weeks *Peripheral Neuropathy in ANCA Vasculitis DOI: http://dx.doi.org/10.5772/intechopen.101241*

Proteinuria >1 g/24 h Creatinemia>140 μmol/L Specific gastrointestinal involvement Specific cardiomyopathy Specific CNS involvement One point for each of these five items when present.
